Transforming Beauty and Wellness with Chin Up! Aesthetics
At Chin Up! Aesthetics, beauty isn't just skin deep—it's about empowering individuals to feel confident in their own skin. Offering an extensive array of aesthetic and cosmetic treatments, the team at Chin Up! Aesthetics has one primary goal: to enhance both the beauty and wellness of each client through safe, effective, and personalised services. With locations in Kennesaw, Decatur, and Smyrna/Vinings, Georgia, Chin Up! Aesthetics has become a trusted name in the greater Atlanta area for transforming lives through advanced aesthetic care.
What sets Chin Up! Aesthetics apart is its commitment to offering the latest in aesthetic medicine, with treatments that address both beauty concerns and overall wellness. Their expertise spans a wide range of services, ensuring every client's unique needs and goals are met. Whether it's reducing the signs of ageing with Botox and dermal fillers or enhancing one's body through cutting-edge body sculpting treatments like Emsculpt Neo, Chin Up! Aesthetics brings the best of both worlds—beauty and wellness—into one seamless experience.
Each treatment plan at Chin Up! Aesthetics is fully customised to the client's needs. With a team of highly skilled professionals, including licensed aestheticians, nurse practitioners, and physician assistants, every client receives individualised attention to achieve the best possible results. The team stays ahead of the curve with ongoing training and utilisation of state-of-the-art technologies, ensuring the most effective and advanced treatments are available to all clients.
'We truly believe in the power of personalization,' said a representative from Chin Up! Aesthetics. 'Every individual's beauty and wellness journey is unique. That's why we take the time to listen to our clients, understand their needs, and design tailored treatment plans that will help them look and feel their best.'
From facial rejuvenation services like Botox/Dysport and dermal fillers to body contouring treatments like Emsculpt Neo, Chin Up! Aesthetics covers a wide array of options. Their innovative treatments like Kybella—a solution for permanently eliminating stubborn fat under the chin—are just a few examples of how the company is pushing the boundaries of what's possible in the world of aesthetic medicine.
Additionally, Chin Up! Aesthetics takes a comprehensive approach to skincare and wellness. Offering Hydrafacial treatments for deep cleansing and hydration or PRP injections for skin rejuvenation, clients can trust that their skin health is being prioritised. Chin Up! Aesthetics also addresses wellness concerns with therapies such as Sculptra, which helps to restore facial volume and improve skin's inner structure, giving clients a youthful glow and renewed confidence.
'We want our clients to feel at ease, knowing they are in the hands of professionals who prioritize both their safety and satisfaction,' continued the representative. 'Our commitment to staying on top of new techniques, equipment, and methods ensures that we can continue to offer the very best in aesthetic and wellness treatments.'
The company's approach isn't just about looking good—it's about feeling good, too. With a team that blends art and science, Chin Up! Aesthetics focuses on achieving natural results that not only enhance beauty but promote a sense of well-being. Whether a client is seeking treatment to address the visible signs of ageing, reduce stubborn fat, or simply rejuvenate their skin, the focus is always on creating results that leave clients feeling confident, refreshed, and empowered.
At Chin Up! Aesthetics, every service is delivered with care and precision, ensuring that each treatment is as effective as it is comfortable. The company's dedication to customer satisfaction is evident, with over 200 five-star reviews from satisfied clients who rave about the transformative results and exceptional service they receive. As an added bonus, flexible payment options, including interest-free financing, make it easier for clients to invest in their beauty and wellness without financial worry.
About Chin Up! Aesthetics
Chin Up! Aesthetics is a premier medspa providing a range of aesthetic and cosmetic treatments designed to enhance both beauty and wellness. With locations in Kennesaw, Decatur, and Smyrna/Vinings, Georgia, the company serves clients across the Atlanta metropolitan area. The team consists of licensed aestheticians, nurse practitioners, and physician assistants who specialise in medical aesthetics. At Chin Up! Aesthetics, each client is treated to a personalised experience, with custom treatment plans designed to meet their unique goals. Services include face, body, skin, and wellness treatments using advanced technology and cutting-edge techniques. With a commitment to client satisfaction and well-being, Chin Up! Aesthetics has earned a reputation for excellence in the industry.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 days ago
- USA Today
More men are seeking out ‘penis filler.' The complications are horrifying doctors.
Dr. Jason Emer, a cosmetic dermatologist and surgeon, still remembers the patient who traveled across state lines, arriving in his office frantic for a fix to the botched procedure that left him deformed. He also remembers the man who was left in so much shame, he couldn't leave the house for six months. And the man with a gruesome hole in his body as a result of necrosis. Cases like these, Emer says, are becoming more common. These men are part of a growing group of patients he's seen lately that are in need of costly corrections for complications that arose from penis filler, a cosmetic treatment meant to enlarge the appearance of the penis. Emer offers the procedure and has been administering it since 2007. He says it's a delicate practice − one that can easily go wrong if not done by a professional with expertise and training. As this cosmetic procedure has become more popular, more men are seeking it out from unqualified providers, experts in the field say. As a result, many have suffered horrifying complications − though barely any want to talk about it. Instead, these patients are left shouldering lasting trauma in silence. "Penis filler is like the breast implants of the early 2000s; more men are having it done but the cultural conversation is still in early stages of normalization," says Chris Bustamante, an aesthetic nurse practitioner and the founder of Lushful Aesthetics. "Unfortunately, we've seen patients who have undergone unsafe penis filler procedures, usually outside the U.S. but also with providers who just 'dabble' with the procedure and don't do it for a living." What health & wellness means for you: Sign up for USA TODAY's Keeping It Together newsletter With such a delicate procedure, complications abound Though still a taboo topic, penis filler has grown in popularity in recent years as more men have come to embrace Botox, plastic surgery and other cosmetic procedures. Yet Emer believes very few providers have mastered it. When the treatment goes wrong, he says, it's usually because the patient sought it from a less-experienced provider at a cheaper cost. Bustamante says he's also seen many with complications who got the treatment done in other countries. "To be able to know how to do it and do it safely, you have to really understand the anatomy, the approach," Emer says. More: Men often struggle with penis insecurity. But no one wants to talk about it. Emer says he sees patients for penis filler about three-to-five times a day. Over half of these patients, he says, come to him for corrections for past treatments from other providers. One man detailed to USA TODAY how he suffered serious complications after getting the cosmetic procedure from people who were trained in the practice by a med spa owner who was not a doctor. After his first round of the treatment in 2021, he was left deformed. The man returned to the same provider to correct the issue, receiving more filler at additional cost. These injections, however, did not help. Successive ones, he says, didn't either. "I was like... absolutely not. This does not look natural to me," says the patient, who asked that we withhold his name to protect his medical privacy. This ordeal lasted years and took a tremendous toll on his personal life. Finally, in 2024, he says Bustamante was able to use filler to right the wrongs of these past providers. More: People are getting black-market silicone injected into their butts. Doctors are horrified. According to Emer, it's not just important to see a provider with extensive experience; it's also important to take a long-term approach to a procedure like this. "You can't just be somebody that has very minimal experience to be able to do this," Emer says. "These clients aren't one-and-done. This is a client that 10 years later can come back to you with an issue." More men are seeking out procedures like these. Why? Emer says he's seen a change in the men coming to him for penis filler. The men who used to come see him had a clear reasoning for seeking out the procedure, but he says now that's changed. "What I find is most people actually want it for themselves, their own self-confidence." Despite the procedure's growing popularity, stigma around it persists. Sean Lathe is one man who says he's had a positive experience after getting the treatment from Bustamante. He has no shame in sharing that he's had it done and wishes more men felt the same way. "I'm very open about mine," Lathe says. "I have no issue talking about it, and I think that's kind of the way it should be." More: Erection shockwave therapy may help with erectile dysfunction, but it's shrouded in shame Bustamante's other patient, however, is just grateful he was able to get his botched procedure corrected. When his current round of filler dissolves, he says he won't be getting any more. "After all of this, I am deciding to just sort of go back to normal," he says. "I really don't need it anymore."
Yahoo
3 days ago
- Yahoo
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) ('Waldencast'), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions. 'We are excited to further diversify Obagi Medical's portfolio of medical-grade skincare with consumer centric, in-office injectable procedures through the introduction of the Obagi Medical Saypha® ChIQ™ and MagIQ™ lines of injectable HA gels,' said Michel Brousset, Co-Founder and CEO of Waldencast. 'Adding proven products into our portfolio increases our addressable market and allows us to deliver solutions for professionals and patients seeking both skincare and aesthetic treatments, all under the trusted Obagi Medical brand.' Obagi Medical's philosophy advocates for a holistic, science-driven approach where potent skincare and professional procedures work in tandem to achieve and maintain optimal skin health and a youthful appearance. These injectable products will play a pivotal role in the evolution of Obagi Medical into an end-to-end, synergistic solution that integrates medical-grade skincare with aesthetic treatments to deliver enhanced outcomes, prolonged results, and greater patient satisfaction. Beyond the two current offerings, the Novaestiq transaction provides access to a future pipeline of novel injectables in North America. Saypha®,2 currently undergoing U.S. Food and Drug Administration (FDA) approval, is recognized globally as a proven, safe and efficacious HA injectable with high levels of patient satisfaction. The new Obagi Medical injectable portfolio is supported by an industry-leading clinical program that reflects the brand's commitment to science-backed innovation. Core pivotal studies are more than twice the size of typical nasolabial fold (NLF) and midface trials and include the highest representation of Fitzpatrick Skin Types I, V, and VI – underscoring Obagi Medical's mission to provide effective solutions for all skin types and tones. Saypha® is distinguished by its proprietary technology delivering advanced HA treatments through a stable 3D matrix designed to provide natural-looking results with optimally balanced gel characteristics. This technology powers a portfolio of clinically proven products that lead in multiple performance categories including high HA content at injection, ideal gel distribution, and consistent injection force and swelling behavior. Saypha®, a product of Croma-Pharma GmbH, is developed and manufactured in Austria and marketed in over 80 countries, leveraging 40 years of expertise in HA-based treatments with more than 110 million syringes produced. This global reach and deep market insight allow for the delivery of trusted, personalized care to patients and professionals worldwide. 'We believe that great results start with great skincare and are perfected with great after care,' said Dr. Suzan Obagi, Chief Medical Director at Obagi Medical. 'By combining Obagi Medical skincare with injectable procedures under the guidance of a qualified professional, patients can achieve more significant, longer-lasting, and natural-looking results. This acquisition also allows our professionals to offer patients more personalized, higher quality and safer products that their customers are looking for.' Obagi Medical's vision is to become the #1 Dermatological Mega Brand uniquely serving all the needs of physicians, patients and consumers globally. It is already the fastest-growing U.S. professional-skincare brand among the top ten in its category.3 This momentum is powered by a three-pronged strategy: anchoring products in dermatological science, introducing breakthrough innovations, and expanding its global reach. Brousset added, 'We are thrilled to introduce this new offering that will strengthen Obagi Medical's market position, drive innovation, and create new growth opportunities in our fast-evolving industry. We see an accelerating global convergence of health, beauty, and aesthetics – an intersection where Obagi Medical is uniquely positioned to lead. We also plan to leverage this acquisition to expand Obagi Medical's footprint.' Transaction DetailsUnder the terms of the definitive agreement relating to the transaction, Waldencast has agreed to acquire Novaestiq in exchange for (1) certain amount of cash payable at closing, (2) certain additional ongoing royalties based on net sales of Saypha® products, and (3) the contingent issuance of Waldencast class A shares (equal to approximately 7% of Waldencast's fully diluted class A shares), based on the receipt of FDA approval relating to the Saypha® products (triggering the issuance of 3,273,000 Waldencast class A shares) and the achievement of cumulative net revenue thresholds of (a) $100 million (triggering the issuance of an additional 3,273,000 Waldencast class A shares) and (b) $200 million (triggering the further issuance of 3,273,000 Waldencast class A shares), respectively, reflecting meaningful long-term commercial targets, with (a) and (b) being earnable until June 20, 2031. The details of the transaction will be summarized in more detail in a Form 6-K that Waldencast will file with the U.S. Securities and Exchange Commission (the 'SEC') following this press release. About WaldencastFounded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Medical and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: . About Obagi MedicalObagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,3 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand's website, 1In preparing for this transaction, Waldencast engaged management consulting services from a reputed global consulting firm. 2Saypha® products are not approved medical devices, and each product has a premarket approval (PMA) application under review by the FDA. 3Among the Top 10 Professional Skin Care Brands in the U.S., according to Kline's 2024 Global Professional Skin Care Series (China, Europe and the U.S.). AdvisorsHolland & Knight LLP is serving as Waldencast's legal advisor, with support from Skadden, Arps, Slate, Meagher & Flom LLP. Experium Capital Advisers is serving as Waldencast's financial advisor. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the intended benefits of the transaction with Novaestiq, the ability to obtain FDA approval for Saypha®, the contingent issuance of Waldencast class A shares, and the growth strategies of Waldencast, including Obagi Medical and Novaestiq. These forward-looking statements generally are identified by the words 'estimates,' 'projects,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'would,' 'should,' 'future,' 'propose,' 'target,' 'goal,' 'objective,' 'outlook' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of Waldencast, Obagi Medical and Novaestiq that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: (i) the inability to recognize the anticipated benefits of the transaction; (ii) the inability to obtain FDA approval for one or both of the Saypha® products; (iii) the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities; (iv) the overall economic and market conditions, sales forecasts and other information about Waldencast's possible or assumed future results of operations or our performance; (v) changes in general economic conditions; (vi) the impact of any international trade or foreign exchange restrictions, the imposition of new or increased tariffs, foreign currency exchange fluctuations; (vii) that the price of Waldencast's securities may be volatile due to a variety of factors, including Waldencast's, Obagi Medical's or Novaestiq's inability to implement their business plans; and (viii) the ability to implement Waldencast's strategic initiatives and continue to innovate Obagi Medical's existing products and anticipate and respond to market trends and changes in consumer preferences. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Waldencast's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025, or in other documents that may be filed or furnished by Waldencast from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Waldencast assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Contacts InvestorsICRinvestors@ MediaICRwaldencast@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-07-2025
- Yahoo
Fresh botulism warning from health chiefs after Botox reactions
Health chiefs have urged people to be aware of the signs and symptoms of botulism after more people suffered reactions following cosmetic procedures involving botulinum toxin, also known as Botox. The new cases: in the east of England and East Midlands; suggest the use of an unlicensed Botox-like product, the UK Health Security Agency (UKHSA) said. They are not thought to be linked to the cases reported in the north east of England last month. Reactions have included severe eyelid drooping, double vision, trouble swallowing, slurred speech and lethargy, which can happen weeks after the procedure. There have been 38 cases of iatrogenic botulism – a rare form of the illness that happens as a result of medical treatment – reported between June 4 and July 14, according to UKHSA data. Dr Gauri Godbole, consultant medical microbiologist at UKHSA, said: 'Botulism related to aesthetic procedures is rare, but it can be serious. 'It is caused by toxins produced by the bacterium clostridium botulinum. 'These toxins, but not the bacteria, are the active ingredient in Botox and similar products. 'Symptoms of botulism can take up to four weeks to develop and if you have had a recent botulinum toxin (Botox-like) treatment and are having symptoms such as difficulty swallowing or breathing, contact NHS 111 for further advice and seek treatment.' Dr Godbole also urged anyone considering having cosmetic procedures to check that their practitioner is licensed. Professor Meghana Pandit, co-national medical director secondary care at NHS England, added: 'When these procedures go wrong, there is a risk of serious infections and permanent scarring, which is why only registered professionals like a doctor, a nurse or pharmacy prescriber should be prescribing these treatments.' Dr Alison Cave, chief safety officer at the Medicines and Healthcare products Regulatory Agency, warned that 'botulinum toxin is a prescription-only medicine and should only be sold or supplied in accordance with a prescription given by an appropriate practitioner such as a doctor or other qualified healthcare professional'. She said: 'Buying botulinum toxin in any other circumstances significantly increases the risk of getting a product which is either falsified or not licensed for use in the UK. 'This means that there are no safeguards to ensure products meet the MHRA's standards for quality and safety. As such, they can endanger the health of the people who take them. 'Our criminal enforcement unit works hard to identify those involved in the illegal trade in medicines and takes robust enforcement action where necessary. This can include criminal prosecution.' The practitioners involved with the latest cases have ceased the procedure and are co-operating with the investigation, the UKHSA said. The agency is advising healthcare staff to ensure they look out for botulism in people who may have had a recent aesthetic procedures. Treatment for the symptoms includes an anti-toxin.
